

**Press Inquiries**

**Barbara Lisi** / 203.259.4554 / blisi@planningsource.com  
**Fred Iannotti** / 802.888.0085 / fiannotti@planningsource.com

**Company Background**

Remicalm LLC, the parent company of Trimira LLC, is a privately held medical diagnostic and imaging device company that was formed for the commercialization of great science. Remicalm recently obtained an exclusive license for cancer diagnostic, screening, imaging, and monitoring technologies from large universities that are affiliated with two world-renowned cancer centers. The three scientists from the institutions that developed this technology serve on the company's Scientific Advisory Board.

The initial Remicalm technology portfolio includes twenty-six issued or pending patents. Sixteen of these issued or pending patents relate to the detection of various types of pre-cancerous conditions (dysplasia) and cancers. The detection is made through the processing of optical fluorescence and reflectance in certain body tissues. In addition, Remicalm has a confocal microscopy platform that will generate future products. Remicalm also is leveraging innovative biospecific contrast agents and nano particles that will impact screening and diagnostics for numerous organ sites. Remicalm has filed additional patent applications for its own development.

Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body. To identify dysplasia and cancer, the core technology provides for development and introduction of cancer screening and diagnostic products that will be able to image cell tissue in a unique manner.

Remicalm's products will improve the likelihood of a cure through early detection and treatment for pre-cancer and cancer. This technology will also decrease false positives and false negatives, which lead to needless and painful biopsies. Remicalm's products are focused on early screening, imaging, and diagnosis of cancers and pre-cancers which exist in the cells that line the internal and external surfaces of the body.

Remicalm analyzes the commercial viability of its science for the market. The company then designs, manufactures, and sells its products through subsidiaries formed for that purpose. **The first subsidiary is Trimira**, which focuses on oral cancer. Other subsidiaries are focused on the screening and diagnosis of cervical, skin, bladder, and gastrointestinal cancers.